One of the most under-addressed areas of care for diabetes patients is the detection and treatment of eye disease. Diabetes remains the leading cause of new-onset blindness in working age adults across industrialized countries, and it is largely an avoidable calamity. Only a fraction of patients with diabetes receive the recommended eye exams that could triage people to appropriate paths of care and prevent major life-altering complications and costs to the health system.
Over the last ten years, clinical and scientific leaders of Joslin Diabetes Center have developed and tested an innovative digital retinal imaging device and clinical service to address a significant patient need: detection and management of diabetic retinopathy and other ocular disorders. Through the Joslin Vision NetworkTM (JVN) Joslin clinicians and scientists discovered and perfected a way for images of patients’ eyes to be captured and evaluated without the need for pupil dilation. In addition, the images can be collected at any site by a trained technician and sent to the JVN Reading and Evaluation Center for rapid diagnostic evaluation. JVN is delivered via custom Joslin software and nonmydriatic cameras.
Joslin Diabetes Center has published numerous studies on JVN’s efficacy and potential to detect other pathologies including age-related macular degeneration (AMD). These reports and other publications have provided full evidence of JVN’s clinical effectiveness. In addition, JVN fits within the 2006 American Diabetes Association’s Medical Standards of Care as an effective tool for evaluating patients for diabetic retinopathy.
Joslin Diabetes Center is now working with primary care physicians, endocrinologists and ophthalmologists to bring this clinical service to patients worldwide.
For more information on bringing JVN to your practice, contact
Joslin Vision Network
Page last updated: January 21, 2017